Welcome to our dedicated page for Hookipa Pharma SEC filings (Ticker: HOOK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding HOOKIPA Pharma’s cutting-edge arenavirus science is challenging enough—digging through dense SEC filings shouldn’t add to the workload. Clinical trial readouts, partnership milestones, and rapid cash burn details hide in hundreds of pages, and tracking HOOKIPA Pharma insider trading Form 4 transactions in real time is even tougher. If you’ve ever wondered, “How do I locate the next HOOKIPA Pharma quarterly earnings report 10-Q filing or the latest 8-K material events explained?” you’re in the right place.
Stock Titan pairs every HOOK filing with AI-powered summaries that translate biotech jargon into plain English. Our platform flags cash-runway updates inside the HOOKIPA Pharma annual report 10-K simplified, highlights pipeline progress in each HOOKIPA Pharma earnings report filing analysis, and surfaces HOOKIPA Pharma executive stock transactions Form 4 within minutes of submission. Prefer raw documents? Access complete 10-K, 10-Q, 8-K, 20-F, S-1, and even HOOKIPA Pharma proxy statement executive compensation disclosures—plus HOOKIPA Pharma Form 4 insider transactions real-time—without leaving the page.
Whether you’re comparing quarter-over-quarter R&D spend, monitoring insider buying before trial milestones, or simply understanding HOOKIPA Pharma SEC documents with AI, our coverage delivers. Investors routinely use the platform to:
- Spot dilution risks hidden in shelf registrations
- Track trial setbacks or breakthroughs announced via 8-K
- Study segment cash flows in each HOOKIPA Pharma quarterly earnings report 10-Q filing
Malte Peters, CEO and director of HOOKIPA Pharma Inc. (HOOK), reported an insider sale. On
HOOKIPA Pharma Inc. filed a Form 144/A reporting a proposed sale of 25,172 shares of common stock to be executed on 08/19/2025 through Maxim Group on the NASDAQ. The filing lists an aggregate market value of $20,155 for the shares and shows 9,789,622 shares outstanding.
The securities were acquired as restricted stock units on 07/22/2024 (amount: 54,347) and the notice states the intended payment is compensation. The filing also discloses a recent sale on 07/23/2025 of 29,176 shares for $26,911. The signer represents no undisclosed material adverse information about the issuer.
HOOKIPA Pharma (HOOK) Form 4: On 22 Jul 2025, Chief Executive Officer and Director Malte Peters sold 29,176 common shares at $0.92 per share (≈ $26.8k proceeds). The sale was executed under a pre-arranged “sell-to-cover” program to satisfy tax-withholding obligations triggered by the vesting of RSUs granted on 22 Jul 2024; therefore it was not a discretionary trade. After the transaction, Peters holds 79,519 shares, all owned directly.
No derivative securities were bought or sold, and no additional corporate developments were disclosed. The filing is routine insider-ownership maintenance rather than a signal of changed outlook, but investors may note the reduced float at the margin.
FAQ
What is the current stock price of Hookipa Pharma (HOOK)?
What is the market cap of Hookipa Pharma (HOOK)?
